Pertussis toxin is a robust and selective inhibitor of high grade glioma cell migration and invasion

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Gilder, Andrew S ^a   Wang, Lei ^a,b   Natali, Letizia ^a,c   Karimi Mostowfi, Nicki ^a   Brifault, Coralie ^a   Gonias, Steven L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PERTUSSIS TOXIN; VIMENTIN; FORMYLPEPTIDE RECEPTOR; FPR2 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; LIPOXIN RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL CONTACT; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FPR2 GENE; GENE; GENE EXPRESSION; GLIOMA CELL; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; CELL MOTION; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; GLIOMA; HUMAN; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GLIOMA; HUMANS; MICROSCOPY, FLUORESCENCE; PERTUSSIS TOXIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LIPOXIN;

EID: 85006325096     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168418     Document Type: Article

References (49)

1. Locht C, Coutte L, Mielcarek N. The ins and outs of pertussis toxin. The FEBS Journal 2011; 278 (23):4668-82. doi: 10.1111/j.1742-4658.2011.08237.x PMID: 21740523
2. Kaslow HR, Burns DL. Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J 1992; 6(9):2684-90. PMID: 1612292
3. Bokoch GM, Katada T, Northup JK, Hewlett EL, Gilman AG. Identification of the predominant substrate for ADP-ribosylation by islet activating protein. J Biol Chem 1983; 258(4):2072-5. PMID: 6296122
4. Ksiazkiewicz M, Gottfried E, Kreutz M, Mack M, Hofstaedter F, Kunz-Schughart LA. Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. Immunobiology 2010; 215(9-10):737-47. doi: 10.1016/j.imbio.2010.05.019 PMID: 20605053
5. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cellular signalling 2004; 16(11):1201-10. doi: 10.1016/j.cellsig.2004.04.007 PMID: 15337520
6. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91(4):521-30. PMID: 9390561
7. Manning TJ Jr., Parker JC, Sontheimer H. Role of lysophosphatidic acid and rho in glioma cell motility. Cell motility and the cytoskeleton 2000; 45(3):185-99. doi: 10.1002/(SICI)1097-0169(200003) 45:3<185::AID-CM2>3.0.CO;2-G PMID: 10706774
8. Stahle M, Veit C, Bachfischer U, Schierling K, Skripczynski B, Hall A, et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci 2003; 116(Pt 18):3835-46. doi: 10. 1242/jcs.00679 PMID: 12902401
9. Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene 2015; 34(31):4078-88. doi: 10.1038/onc.2014.336 PMID: 25347738
10. Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinasetype plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A 2011; 108(38):15984-9. doi: 10.1073/pnas.1113416108 PMID: 21896743
11. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 2002; 99(3):1359-64. doi: 10.1073/pnas.022652999 PMID: 11818541
12. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Frontiers in bioscience 2009; 14:4575-87.
13. Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 1997; 86(3):525-31. doi: 10.3171/jns.1997.86.3.0525 PMID: 9046311
14. Kost CK Jr., Herzer WA, Li PJ, Jackson EK. Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat. Clinical and experimental pharmacology & physiology 1999; 26(5-6):449-55.
15. Orozco-Morales M, Sanchez-Garcia FJ, Guevara-Salazar P, Arrieta O, Hernandez-Pedro NY, Sanchez-Garcia A, et al. Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin. Journal of cancer research and clinical oncology 2012; 138(1):23-33. doi: 10.1007/s00432-011-1069-y PMID: 21947268
16. Magana-Maldonado R, Manoutcharian K, Hernandez-Pedro NY, Rangel-Lopez E, Perez-De la Cruz V, Rodriguez-Balderas C, et al. Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma. Journal of cancer research and clinical oncology 2014; 140(2):291-301. doi: 10.1007/s00432-013-1565-3 PMID: 24337403
17. Otto T, Lummen G, Kalble T, Recker F, Krege S, Bex A, et al. Intravesical therapy with pertussis toxin before radical cystectomy in patients with bladder cancer: a Phase I study. Urology 1999; 54(3):458-60. PMID: 10475354
18. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11 (4):1462-6. doi: 10.1158/1078-0432.CCR-04-1737 PMID: 15746047
19. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 1990; 87(21):8602-6. PMID: 2236070
20. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994; 91(16):7727-31. PMID: 8052651
21. Pala A, Karpel-Massler G, Kast RE, Wirtz CR, Halatsch ME. Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma. Cancers 2012; 4(2):523-30. doi: 10.3390/ cancers4020523 PMID: 24213322
22. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 2010; 107(6):2616-21. doi: 10.1073/pnas.0914356107 PMID: 20133782
23. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002; 1(3):269-77. PMID: 12086863
24. Schildge S, Bohrer C, Beck K, Schachtrup C. Isolation and culture of mouse cortical astrocytes. J Vis Exp 2013; 71:50079
25. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272(5):2927-35. PMID: 9006938
26. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, et al. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res 2015; 75 (2):394-404. doi: 10.1158/0008-5472.CAN-14-2004 PMID: 25432173
27. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annual review of cell biology 1993; 9:541-73. doi: 10.1146/annurev.cb. 09.110193.002545 PMID: 8280471
28. Webb D, Nguyen D, Gonias S. Extracellular signal-regulated kinase functions in the urokinase receptordependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci 2000; 113(Pt 1):123-34.
29. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3(12):932-43. doi: 10.1038/nrm977 PMID: 12461559
30. Reynolds BA, Rietze RL. Neural stem cells and neurospheres-re-evaluating the relationship. Nature methods 2005; 2(5):333-6. doi: 10.1038/nmeth758 PMID: 15846359
31. Chaichana K, Zamora-Berridi G, Camara-Quintana J, Quinones-Hinojosa A. Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem cells 2006; 24(12):2851-7. doi: 10.1634/stemcells.2006-0399 PMID: 16945995
32. Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH, et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008; 265(1):124-34. doi: 10.1016/j.canlet. 2008.02.010 PMID: 18343028
33. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain: a journal of neurology 2010; 133(Pt 4):983-95.
34. Zhao J, Zhang L, Dong X, Liu L, Huo L, Chen H. High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma. Appl Immunohistochem Mol Morphol 2016.
35. Mazar AP, Ahn RW, O'Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des 2011; 17 (19):1970-8. PMID: 21711234
36. Persson M, Juhl K, Rasmussen P, Brandt-Larsen M, Madsen J, Ploug M, et al. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer. Molecular pharmaceutics 2014; 11(8):2796-806. doi: 10.1021/mp500177c PMID: 24955765
37. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11(1):23-36. doi: 10.1038/nrm2821 PMID: 20027185
38. Gonias SL, Hu J. Urokinase receptor and resistance to targeted anticancer agents. Frontiers in pharmacology 2015; 6:154. doi: 10.3389/fphar.2015.00154 PMID: 26283964
39. Jo M, Thomas K, Marozkina N, Amin T, Silva C, Parsons S, et al. Dynamic assembly of the urokinasetype plasminogen activator signaling receptor complex determines the mitogenic activity of urokinasetype plasminogen activator. J Biol Chem 2005; 280(17):17449-57. doi: 10.1074/jbc.M413141200 PMID: 15728176
40. Ruoslahti E. Brain extracellular matrix. Glycobiology 1996; 6(5):489-92. PMID: 8877368
41. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009; 1788(4):842-57. doi: 10.1016/j.bbamem.2008.10.022 PMID: 19061857
42. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993; 72(4):551-60. PMID: 7679952
43. Linthicum DS, Munoz JJ, Blaskett A. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cellular immunology 1982; 73(2):299-310. PMID: 6891621
44. Yong T, Meininger GA, Linthicum DS. Enhancement of histamine-induced vascular leakage by pertussis toxin in SJL/J mice but not BALB/c mice. J Neuroimmunol 1993; 45(1-2):47-52. PMID: 8331165
45. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66(19):9339-44. doi: 10.1158/0008-5472.CAN-06-3126 PMID: 16990346
46. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8(10):755-68. doi: 10.1038/nrc2499 PMID: 18784658
47. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444(7120):756-60. doi: 10. 1038/nature05236 PMID: 17051156
48. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular cancer 2006; 5:67. doi: 10.1186/1476-4598-5-67 PMID: 17140455
49. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13(10):714-26. doi: 10.1038/nrc3599 PMID: 24060863